ASX:IMM Immutep (IMM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Immutep Stock (ASX:IMM) 30 days 90 days 365 days Advanced Chart Get Immutep alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.15 million shsAverage VolumeN/AMarket Capitalization$465.79 millionP/E RatioN/ADividend Yield6.41%Price TargetN/AConsensus RatingN/A Company OverviewImmutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Read More… Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter. Email Address IMM Stock News HeadlinesImmutep Limited: Immutep Quarterly Activities Report Q3 FY25April 30 at 3:54 PM | finanznachrichten.deImmutep announces first patient dosed in TACTI-004 Phase III trialMarch 27, 2025 | markets.businessinsider.comThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.May 3, 2025 | Stansberry Research (Ad)Health Check: Bargain hunters flock to 4D Medical’s discounted raisingMarch 25, 2025 | msn.comImmutep notches upward on first lung cancer patient dosingMarch 25, 2025 | msn.comImmutep announces poster presentation for the TACTI-004 Phase III trialMarch 21, 2025 | markets.businessinsider.comImmutep Ltd (PRRUF) Receives a Buy from Canaccord GenuityMarch 7, 2025 | markets.businessinsider.comWhy Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?January 27, 2025 | msn.comSee More Headlines IMM Stock Analysis - Frequently Asked Questions How were Immutep's earnings last quarter? Immutep Limited (ASX:IMM) released its quarterly earnings data on Wednesday, February, 27th. The company reported $0.00 earnings per share (EPS) for the quarter. Immutep had a negative trailing twelve-month return on equity of 34.61% and a negative net margin of 1,138.04%. What other stocks do shareholders of Immutep own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immutep investors own include ICL Group (ICL), Geron (GERN), Enphase Energy (ENPH), Immutep (IMMP), Seres Therapeutics (MCRB), OPKO Health (OPK) and Albireo Pharma (ALBO). Company Calendar Last Earnings2/27/2019Today5/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:IMM CIKN/A Webwww.primabiomed.com.au Phone61 2 8315 7003FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-5.92Net Income$-42,720,000.00 Net Margins-1,138.04% Pretax MarginN/A Return on Equity-34.61% Return on Assets-16.67% Debt Debt-to-Equity Ratio0.90 Current Ratio13.81 Quick Ratio13.78 Sales & Book Value Annual Sales$3.84 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.83 Book ValueA$0.16 per share Price / BookN/AMiscellaneous Outstanding Shares1,450,000,000Free FloatN/AMarket Cap$465.79 million OptionableNot Optionable Beta1.93 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (ASX:IMM) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.